To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. VWR will not lift restrictions for residential shipping addresses.
Specifications
- Description:Celltrion DiaTrust™ COVID-19 Ag rapid test
- Cat. no.:76514-476
Specifications
About this item
Rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV2 in human nasopharyngeal swab specimens directly collected from individuals who are suspected of COVID-19.
- Authorized Settings: Point of Care Testing (H,M,W)
- Lateral Flow Immunoassay, (No additional instrument required)
- Test Time: Read results at 15 mins
- Sample Type: Nasopharyngeal Swab (NPS)
- Intended Use: Detection of Antigen from SARS-CoV-2
Celltrion DiaTrust™ COVID-19 Ag Rapid Test is a rapid test based on lateral flow immunoassay intended for the qualitative detection of nucleocapsid and receptor binding domains (RBDs) from the SARS-CoV-2 spike proteins in human nasopharyngeal swab specimen. Results are for the identification of SARS-CoV-2 nucleocapsid and RBD protein antigen.
The Celltrion DiaTrust™ COVID-19 Ag Rapid Test is validated for use from direct specimens testing without transport media, and does not differentiate between SARS-CoV and SARS-CoV-2. This Rapid Test is intended for use by medical professionals or trained operators who are proficient in performing tests, trained clinical laboratory personnel, or individuals trained in POC settings. Variants are anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation.
Clinical Sensitivity: 93.33% (28/30)
(95% CI: 78.7-98.2%)
Clinical Specificity: 99.03% (102/103)
(95% CI: 94.7-99.8%)